Lifespin Announces Expansion of Laboratory Testing Capability

New investments in testing infrastructure will enable Lifespin to analyze up to 300,000 patient samples annually to support its metabolic profiling services

BOSTON–(BUSINESS WIRE)–Lifespin GmbH, based in Regensburg (Germany), with offices in Boston, Massachusetts, announced today that it has installed additional Nuclear Magnetic Resonance (NMR) equipment which will double Lifespin’s annual laboratory testing capacity.

Lifespin will now be able to scan and create the corresponding digitized, quantitative metabolic profiles involving as many as 300,000 human samples per year.

“These additional resources will support our recently launched commercial services which, for the first time, will provide the pharmaceutical and biobanking industries with access to our proprietary metabolic database, as well as to our advanced interpretive software to assist in various phases of drug research, development, and manufacturing,” said Dr. Ali Tinazli, CEO of Lifespin GmbH.

Achieving Speed, Cost-Effectiveness, and Scalability

Because Lifespin’s instrument systems are fully automated, operate 24/7, and require very little maintenance and offline times, its services are highly automated, scalable, and cost-effective for multiparameter quantification in biofluids.

“Our business model is driven by an understanding that scalable infrastructures, like those we have and are developing, are an indispensable prerequisite to foster clinical accessibility, affordability, and market penetration of precision medicine tools,” said Dr. Roland Geyer, Lifespin’s Chief Operating Officer. “With additional analytical lines, Lifespin will be able to accelerate the clinical availability of our database to prospective partners, and digitize large clinical cohorts, without limiting our extraordinary turnaround times and services.”

Lifespin is working to build new precision medicine tools based on quantitative metabolic profiles and proprietary algorithms to assist in the early detection of diseases and monitoring the efficacy of health treatments. To facilitate these services, the company has established one of the largest and most comprehensive databases of metabolic health profiles across healthy and diseased individuals covering multiple age and gender groups as well as specific diseases in neurology, oncology, and inflammation.

Lifespin, a deep data company that maps human health based on snapshots of metabolic states, has built one of the largest and most comprehensive databases of metabolic health profiles across healthy and diseased individuals covering multiple age and gender groups as well as specific diseases in neurology, oncology, and inflammation. Utilizing proprietary technology, Lifespin is performing quantitative in-house measurements of metabolomes, digitizing metabolic profiles that include billions of metabolic relationships. These digital metabolic profiles allow systematic mapping across various health conditions and may enable differential diagnosis and early detection of health conditions, staging of diseases, monitoring of treatment success and personalized medicine. Lifespin’s advisory board consists of key opinion leaders such as James Rothman (Nobel Laureate in Physiology/Medicine, Sterling Professor of Cell Biology, Yale University, New Haven, CT USA) and other prominent leaders in the relevant fields of study. Lifespin’s products offered to-date are for Research Use Only (RUO) and are not for use in diagnostics. Current developments in oncology and neurology yielding first regulated products in human diagnostics are expected for 2023.

Contacts

Dr. Ali Tinazli, CEO, [email protected] , +1 310-467-1112 and +49-160-257-3458

David Paine, Public Relations, PaineLab, [email protected], +1 949-233-0050